Manufacturing tweaks to subcutaneous Tecentriq delay Roche's US launch, CMC processes to be updated by year’s end
Roche informed its drug delivery tech partner Halozyme Therapeutics that the US launch of the subcutaneous version of Tecentriq will be delayed to next year …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.